BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 24, 2005
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 10/21 cls
Actelion (SWX:ATLN) Morgan Stanley Daniel Mahony Price target Overweight 6% CHF142
Mahony raised his target to CHF166 from CHF161 after the cardiovascular company reported 3Q05 diluted EPS of CHF1.63, up 50% from CHF1.09 in the same period last year.
Amgen (AMGN) Baird Christopher Raymond Other Market outperform -3% $73.37
Legg Mason Edward Nash Other Buy
SG Cowen Eric Schmidt Other NA
Susquehanna Soham Pandya Other NA
Raymond raised his FY06 EPS estimate to $3.70 from $3.62 after AMGN reported 3Q05 EPS of $0.85, beating his estimate by $0.02. He said the bellwether has a reasonable valuation and recommended aggressive buying on price weakness.
Nash lowered his FY05 and FY06 revenue estimates to $12.5B from $12.6B and to $14B from $14.3B on the earnings news. He lowered his FY06 Epogen sales estimates to $2.3B from $2.6B to account for greater than expected cannibalization by second-generation anemia drug Aranesp.
Schmidt raised his FY06 EPS estimate to $3.75 from...

Read the full 1070 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >